---
title: "GNS Webinar: Using Causal AI to answer the Patient Response Question"
---

[![whitelogo](https://info.aitiabio.com/hs-fs/hubfs/whitelogo.png?width=300&height=37&name=whitelogo.png "whitelogo")](http://www.gnshealthcare.com)

![iStock-10171937181](https://info.aitiabio.com/hs-fs/hubfs/iStock-10171937181.jpg?width=1000&name=iStock-10171937181.jpg "iStock-10171937181")

# **Who does your drug work for?** Using Causal AI to Answer the Patient Response Question November 12, 2019 | 1:00PM EST

 

**Who does your drug work for?**

Using Causal AI to answer  the Patient Response Question

Biopharma companies have long struggled to identify the best responders for specific drugs.  Fortunately, data availability and technological advancements are now advanced enough for machine learning to help predict patient response using causal AI. The implications of correctly identifying markers of patient response are huge and include improved clinical trials design, timely patient recruitment, data and models for better supporting HTA and other market access submissions, reducing the cost of care and saving lives.  

Join this webinar, to hear why our distinguished speaker Dr. Alan Venook, Former Chair of the Alliance for Clinical Trials in Oncology, Madden Family Distinguished Professor of Medical Oncology and Translational Research at the University of California-San Francisco, chose to join forces with GNS Healthcare and how together, they used GNS’ causal AI platform to better understand treatment response in metastatic colorectal cancer patients.   

 

 

REGISTER NOW

# During this 60-minute webinar we will cover:

- What causal AI is, how it differs from predictive analytics, and its applicability to pharma’s toughest questions  
- How causal AI uncovers the mechanistic underpinning of patient treatment response 
- A specific example of causal AI in practice from the Alliance for Clinical Oncology and GNS Healthcare collaboration in colorectal cancer  
- How to think about using causal AI to gain unique insights from failed clinical trials 
- How identifying drivers of response can improve clinical practice and drug development   

# Speakers

![alanvernook](https://info.aitiabio.com/hs-fs/hubfs/GNS%20PM%20Industry%20Forum/alanvernook.png?width=202&name=alanvernook.png "alanvernook")

### Alan P. Venook, MD

### Study Chair for the CALGB/SWOG 80405 (Alliance) study, Madden Family Distinguished Professor of Medical Oncology and Translational Research at the University of California-San Francisco, and Shorenstein Associate Director for Program Development at the Helen Diller Family Comprehensive Cancer Center

![rahul](https://info.aitiabio.com/hs-fs/hubfs/rahul.png?width=200&name=rahul.png "rahul")

### Rahul Das, PhD

### Associate Director of Precision Medicine

© GNS Healthcare

196 Broadway, Cambridge, MA 02139[| https://www.gnshealthcare.com/](https://www.gnshealthcare.com/)